AIM: The aim of our study was to investigate whether serum levels of soluble tumor necrosis factor α receptor (sTNFR) 1 and 2 are markers for renal dysfunction in type 2 diabetic patients without overt proteinuria. METHODS: Japanese type 2 diabetic patients without overt proteinuria (n = 168) enrolled in the prospective observational follow-up study in 2001 were retrospectively analyzed. At baseline, the serum levels of sTNFR1 and sTNFR2 were measured by sandwich ELISA. The associations between these markers and change in estimated glomerular filtration rate (eGFR) after 5 years were evaluated. RESULTS: The levels of sTNFR1 and sTNFR2 closely correlated. At baseline, sTNFR1 and sTNFR2 associated inversely with eGFR. After 5 years, patients with high level of both sTNFR1 and sTNFR2 showed a greater decline in eGFR (-13.8 ± 15.5% versus -8.5 ± 11.8%, P = 0.027) and a 4-fold higher risk for a GFR decline of ≥ 25% than those with high level of only one receptor or low level of both receptors. These associations were enhanced in diabetic women. CONCLUSIONS: The higher levels of sTNFR1 and sTNFR2 were associated with a greater decline in eGFR in type 2 diabetic patients without proteinuria, especially in diabetic women.
AIM: The aim of our study was to investigate whether serum levels of soluble tumornecrosis factor α receptor (sTNFR) 1 and 2 are markers for renal dysfunction in type 2 diabeticpatients without overt proteinuria. METHODS: Japanese type 2 diabeticpatients without overt proteinuria (n = 168) enrolled in the prospective observational follow-up study in 2001 were retrospectively analyzed. At baseline, the serum levels of sTNFR1 and sTNFR2 were measured by sandwich ELISA. The associations between these markers and change in estimated glomerular filtration rate (eGFR) after 5 years were evaluated. RESULTS: The levels of sTNFR1 and sTNFR2 closely correlated. At baseline, sTNFR1 and sTNFR2 associated inversely with eGFR. After 5 years, patients with high level of both sTNFR1 and sTNFR2 showed a greater decline in eGFR (-13.8 ± 15.5% versus -8.5 ± 11.8%, P = 0.027) and a 4-fold higher risk for a GFR decline of ≥ 25% than those with high level of only one receptor or low level of both receptors. These associations were enhanced in diabeticwomen. CONCLUSIONS: The higher levels of sTNFR1 and sTNFR2 were associated with a greater decline in eGFR in type 2 diabeticpatients without proteinuria, especially in diabeticwomen.
Authors: Axel C Carlsson; Juan-Jesús Carrero; Peter Stenvinkel; Matteo Bottai; Peter Barany; Anders Larsson; Johan Ärnlöv Journal: Cardiorenal Med Date: 2015-01-30 Impact factor: 2.041
Authors: Axel C Carlsson; Tobias E Larsson; Johanna Helmersson-Karlqvist; Anders Larsson; Lars Lind; Johan Ärnlöv Journal: J Am Soc Nephrol Date: 2014-02-07 Impact factor: 10.121
Authors: Axel C Carlsson; Lina Nordquist; Tobias E Larsson; Juan-Jesús Carrero; Anders Larsson; Lars Lind; Johan Ärnlöv Journal: Cardiorenal Med Date: 2015-07-31 Impact factor: 2.041
Authors: Yun Jung Oh; Jung Nam An; Clara Tammy Kim; Seung Hee Yang; Hajeong Lee; Dong Ki Kim; Kwon Wook Joo; Jin Ho Paik; Shin-Wook Kang; Jung Tak Park; Chun Soo Lim; Yon Su Kim; Jung Pyo Lee Journal: PLoS One Date: 2015-07-15 Impact factor: 3.240
Authors: Daniel Medenwald; Matthias Girndt; Harald Loppnow; Alexander Kluttig; Sebastian Nuding; Daniel Tiller; Joachim J Thiery; Karin H Greiser; Johannes Haerting; Karl Werdan Journal: PLoS One Date: 2014-09-26 Impact factor: 3.240
Authors: Axel C Carlsson; Carl Johan Östgren; Fredrik H Nystrom; Toste Länne; Pär Jennersjö; Anders Larsson; Johan Ärnlöv Journal: Cardiovasc Diabetol Date: 2016-02-29 Impact factor: 9.951